Home > Dermatology > AAD 2020 > Novel IL-23 blocker risankizumab highly effective and tolerable in psoriasis

Novel IL-23 blocker risankizumab highly effective and tolerable in psoriasis

In the phase 3 IMMerge trial, risankizumab showed non-inferiority to secukinumab after 16 weeks and superiority in all assessed efficacy endpoints at week 52 in patients with moderate-to-severe plaque psoriasis [1,2].

“Although we have many efficacious drugs in psoriasis now, it is important to know which drug is used when, and of course, which drug is better than others,” said Prof. Richard Warren (University of Manchester, UK). Thus, head-to head studies are important. In this current head-to-head trial, the IL-23 blocker risankizumab was compared with the IL-17 blocker secukinumab in adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

Participants (n=327) were randomised to receive either 150 mg risankizumab at weeks 0, 4, and every 12 weeks thereafter or 300 mg secukinumab weekly from week 0 to 4, and every 4 weeks thereafter. Primary outco...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on